Control of kidney fibrosis in the mouse unilateral urethral obstruction model with the novel AP-1 inhibitor

新型 AP-1 抑制剂控制小鼠单侧尿道梗阻模型中的肾纤维化

• 批准号: 22791499
• 负责人: MAEDA Takahiro
• 金额: $ 2.58万
• 依托单位: Keio University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2010
• 资助国家: 日本
• 起止时间: 2010 至 2011
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22791499/
• 关键词: 水腎症; 線維化

The unilateral ureteral obstructive(UUO) model of the mouse was created. We evaluated the natural time course of renal fibrosis after UUO operation. Renal fibrosis was occurred in both renal medulla and cortex at least from the 3rd day after UUO creation. DHMEQ treatment decreased the interstitial fibrosis, tubular apoptosis and proliferation as compared with control group in the non-immune nephritis model. On the other hand, DTCM(dodecylthiocarbonyl methyl) did not achieve the significant effect against the renal fibrosis compared with the control group. I thought that the further detailed examination of the medication method, an administration route, and a dosing period was required.

建立小鼠单侧输尿管梗阻（UUO）模型。我们评估了UUO手术后肾纤维化的自然时程。至少从UUO产生后第3天开始，肾髓质和皮质均发生肾纤维化。在非免疫性肾炎模型中，与对照组相比，DHMEQ治疗减少了间质纤维化、肾小管凋亡和增殖。另一方面，与对照组相比，DTCM（十二烷基硫代羰基甲基）没有达到显着的抗肾纤维化效果。我认为需要对用药方法、给药途径、给药周期进行进一步详细的检查。